Abstract
Aiming to estimate the prevalence of anti-SARS-CoV-2 antigens and antibodies among incarcerated individuals, an institution-based serological survey was conducted in seven prison units across four municipalities in the state of Piauí, Brazil, from April to October 2022. A probabilistic cluster sampling method was adopted. Interviews, rapid tests, and serological assays were performed to detect anti-SARS-CoV-2 antigens and antibodies. Prevalence rates, statistical associations using the chi-square test, and prevalence ratios through Poisson regression were calculated. Among the 848 participants, antigen prevalence was 1.1%. The prevalence of anti-SARS-CoV-2 antibodies ranged from 6.5% (IgM-S) to 98.9% (IgG-S). No significant differences were observed in antigen prevalence. The prevalence of IgG-N and IgG-S antibodies was higher among inmates in Teresina (PR=1.41; 95%CI: 1.08-1.46; PR=1.03; 95%CI: 1.01-1.05). Receiving at least two doses of a COVID-19 vaccine increased antibody seropositivity (IgM-S PR=2.08; 95%CI: 1.01-4.29; IgG-N PR=1.26; 95%CI: 1.08-1.46; IgG-S PR=1.02; 95%CI: 1.01-1.04). These findings reinforce the positive impact of vaccination and other control measures implemented in the incarcerated population during the COVID-19 pandemic.
Funding Information
  • Fundação de Amparo à Pesquisa do Piauí
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

This publication has 17 references indexed in Scilit: